Search Results - "PASSARELL, Julie"

Model‐Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis by Gandhi, Yash, Passarell, Julie A., Roy, Amit, Murthy, Bindu

“…The selective T‐cell costimulation modulator abatacept is approved for treatment of adult rheumatoid arthritis (RA) and polyarticular juvenile idiopathic…”
Get full text

Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function by Flanagan, Shawn, McKee, Edward E, Das, Debaditya, Tulkens, Paul M, Hosako, Hiromi, Fiedler-Kelly, Jill, Passarell, Julie, Radovsky, Ann, Prokocimer, Philippe

“…Prolonged treatment with the oxazolidinone linezolid is associated with myelosuppression, lactic acidosis, and neuropathies, toxicities likely caused by…”
Get full text

Pharmacokinetic–pharmacodynamic (dipeptidyl peptidase‐4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once‐weekly administered omarigliptin by Jain, Lokesh, Chain, Anne S.Y., Tatosian, Daniel A., Hing, Jeremy, Passarell, Julie A., Kauh, Eunkyung A., Lai, Eseng

“…Aims To characterize the population pharmacokinetics (PK) and pharmacodynamics (PD) of the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin in…”
Get full text

Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects by Flanagan, Shawn, Minassian, Sonia L., Passarell, Julie A., Fiedler‐Kelly, Jill, Prokocimer, Philippe

Get full text

Population Pharmacokinetics and Exposure–Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial‐Onset Seizures by Sunkaraneni, Soujanya, Ludwig, Elizabeth A., Passarell, Julie A., Blum, David, Grinnell, Todd, Fiedler‐Kelly, Jill

“…Eslicarbazepine acetate (ESL) is a once‐daily oral antiepileptic drug (AED) indicated for partial‐onset seizures (POS). ESL pharmacokinetics (PK) and…”
Get full text

Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma by Owen, Joel S, Melhem, Murad, Passarell, Julie A, D'Andrea, Denise, Darwish, Mona, Kahl, Bradley

“…Purpose The pharmacokinetic profiles of bendamustine and active metabolites were defined in patients with rituximab-refractory, relapsed indolent B-cell…”
Get full text

Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults by Hopkins, Seth C., Sunkaraneni, Soujanya, Skende, Estela, Hing, Jeremy, Passarell, Julie A., Loebel, Antony, Koblan, Kenneth S.

“…Background and Objectives Dasotraline is a novel inhibitor of dopamine and norepinephrine reuptake currently being investigated in clinical studies for the…”
Get full text

Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19 by Sager, Jennifer E., El‐Zailik, Asma, Passarell, Julie, Roepcke, Stefan, Li, Xiaobin, Aldinger, Melissa, Nader, Ahmed, Skingsley, Andrew, Alexander, Elizabeth L., Yeh, Wendy W., Mogalian, Erik, Garner, Chad, Peppercorn, Amanda, Shapiro, Adrienne E., Reyes, Maribel

“…Sotrovimab is a recombinant human monoclonal antibody that has been shown to prevent progression to hospitalization or death in non‐hospitalized high‐risk…”
Get full text

Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania by Periclou, Antonia, Willavize, Susan, Jaworowicz, David, Passarell, Julie, Carrothers, Timothy, Ghahramani, Parviz, Durgam, Suresh, Earley, Willie, Kapás, Margit, Khariton, Tatiana

“…Population pharmacokinetic/pharmacodynamic modeling (via NONMEM) was used to describe longitudinal exposure‐response relationships for total cariprazine (sum…”
Get full text

Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus Bacteremia by BHAVNANI, Sujata M, PASSARELL, Julie A, OWEN, Joel S, LOUTIT, Jeffrey S, PORTER, Steven B, AMBROSE, Paul G

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections by Ortiz-Covarrubias, Alejandro, Fang, Edward, Prokocimer, Philippe G., Flanagan, Shawn D., Zhu, Xu, Cabré-Márquez, Jose Francisco, Tanaka, Toshiaki, Passarell, Julie, Fiedler-Kelly, Jill, Nannini, Esteban C.

“…Acute bacterial skin and skin structure infections are caused mainly by Gram-positive bacteria which are often treated with intravenous vancomycin, daptomycin,…”
Get full text

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment by Fetterly, Gerald J., Owen, Joel S., Stuyckens, Kim, Passarell, Julie A., Zannikos, Peter, Soto-Matos, Arturo, Izquierdo, Miguel Angel, Perez-Ruixo, Juan Jose

“…Purpose Reversible transient elevations in transaminases have been observed after trabectedin administration. A semimechanistic pharmacokinetic and…”
Get full text

Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy by Sunkaraneni, Soujanya, Passarell, Julie A, Ludwig, Elizabeth A, Fiedler-Kelly, Jill, Pitner, Janet K, Grinnell, Todd A, Blum, David

“…Eslicarbazepine acetate (ESL) is a once-daily (QD) oral antiepileptic drug (AED) indicated for partial-onset seizures (POS). Clinical studies of gradual…”
Get full text

Application of patient population-derived pharmacokinetic–pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci by Ambrose, Paul G, Meagher, Alison K, Passarell, Julie A, Van Wart, Scott A, Cirincione, Brenda B, Bhavnani, Sujata M, Ellis-Grosse, Evelyn

“…Abstract Correctly determined susceptibility breakpoints are important to both the individual patient and to society at large. A previously derived patient…”
Get full text

Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis by Roepcke, Stefan, Passarell, Julie, Walker, Helen, Flanagan, Shawn

“…Rezafungin is a chemically and metabolically stable echinocandin with a longer half-life than other echinocandins, allowing for a once-weekly intravenous…”
Get full text

Use of a clinically derived exposure–response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints by Ambrose, Paul G, Meagher, Alison K, Passarell, Julie A, Wart, Scott A. Van, Cirincione, Brenda B, Rubino, Chris M, Korth-Bradley, Joan M, Babinchak, Timothy, Ellis-Grosse, Evelyn

“…Abstract Potential tigecycline-Enterobacteriaceae susceptibility breakpoints were evaluated using 2 approaches, which differed in the nature of the…”
Get full text

Challenges in the transition to model-based development by Grasela, Thaddeus H, Fiedler-Kelly, Jill, Walawander, Cynthia A, Owen, Joel S, Cirincione, Brenda B, Reitz, Kathleen E, Ludwig, Elizabeth A, Passarell, Julie A, Dement, Charles W

“…Practitioners of the art and science of pharmacometrics are well aware of the considerable effort required to successfully complete modeling and simulation…”
Get full text

Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study by Darwish, Mona, Bugarski-Kirola, Dragana, Passarell, Julie, Owen, Joel, Jaworowicz, David, DeKarske, Daryl, Stankovic, Srdjan

“…Abstract Purpose/Background Pimavanserin is a selective serotonin 5-HT 2A receptor inverse agonist/antagonist being investigated in patients with negative…”
Get full text

Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study by Darwish, Mona, Bugarski-Kirola, Dragana, Passarell, Julie, Owen, Joel, Jaworowicz, David, DeKarske, Daryl, Stankovic, Srdjan

Get full text

Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma by Hamuro, Lora, Hu, Zheyi, Passarell, Julie, Barcomb, Heather, Zhang, Joshua, Goldstein, Shay, Bello, Akintunde, Roy, Amit, Zhu, Li

“…A benefit:risk assessment for a less-frequent nivolumab 480 mg every 4 weeks + cabozantinib 40 mg every day dosing regimen was predicted using modeling and…”
Get full text